Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Investors Business Daily
Investors Business Daily
Business
INVESTOR'S BUSINESS DAILY

Alkermes Shows Rising Relative Price Performance; Still Shy Of Key Benchmark

Alkermes saw a welcome improvement to its Relative Strength (RS) Rating on Friday, rising from 69 to 74.

This proprietary rating tracks technical performance by showing how a stock's price movement over the last 52 weeks compares to that of the other stocks in our database.

Over 100 years of market history reveals that the market's biggest winners tend to have an RS Rating north of 80 as they begin their biggest runs. See if Alkermes can continue to rebound and clear that threshold.

How To Invest In Stocks In Both Bull And Bear Markets

Alkermes is not currently showing a potential buy point. See if the stock goes on to build a base that could spark a new run.

Earnings growth declined in the most recent quarter from -8% to -16%. But sales moved higher, from -35% to -1%.

The company holds the No. 28 rank among its peers in the Medical-Biomed/Biotech industry group. Catalyst Pharmaceuticals, Halozyme Therapeutics and ADMA Biologics are among the top 5 highly rated stocks within the group.

RELATED:

Biotech And Pharmaceutical Industry And Stock News

Which Stocks Are Showing Rising Relative Strength?

Why Should You Use IBD's Relative Strength Rating?

How Relative Strength Line Can Help You Judge A Stock

Ready To Grow Your Investing Skills? Join An IBD Meetup Group!

Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.